14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:TSRO
Delisted

TESARO Fund Price (Quote)

$74.96
+0 (+0%)
At Close: Feb 13, 2019

Range Low Price High Price Comment
30 days $0.0060 $169.56 Wednesday, 13th Feb 2019 TSRO stock ended at $74.96. During the day the stock fluctuated 0% from a day low at $74.96 to a day high of $74.96.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical TESARO prices

Date Open High Low Close Volume
Jan 08, 2019 $74.65 $74.65 $74.32 $74.41 3 621 840
Jan 07, 2019 $74.56 $74.77 $74.47 $74.66 2 367 930
Jan 04, 2019 $74.37 $74.84 $74.14 $74.80 3 719 582
Jan 03, 2019 $74.32 $74.65 $74.00 $74.02 2 599 549
Jan 02, 2019 $74.05 $74.40 $73.76 $74.32 2 440 879
Dec 31, 2018 $73.68 $74.25 $73.46 $74.25 1 731 126
Dec 28, 2018 $73.22 $75.16 $73.08 $73.80 2 098 949
Dec 27, 2018 $73.23 $73.44 $72.93 $73.37 3 067 465
Dec 26, 2018 $73.27 $73.50 $73.04 $73.49 2 631 484
Dec 24, 2018 $72.77 $73.43 $72.76 $73.11 1 084 932
Dec 21, 2018 $73.30 $73.38 $72.59 $72.69 4 232 993
Dec 20, 2018 $73.00 $73.46 $72.95 $73.10 4 021 485
Dec 19, 2018 $73.76 $73.76 $72.62 $72.89 4 882 271
Dec 18, 2018 $73.74 $74.01 $73.26 $73.46 3 637 168
Dec 17, 2018 $73.72 $74.23 $73.66 $73.66 3 641 979
Dec 14, 2018 $74.38 $74.44 $73.59 $73.69 4 834 002
Dec 13, 2018 $74.30 $74.50 $74.14 $74.49 3 666 036
Dec 12, 2018 $74.26 $74.55 $74.17 $74.31 4 083 876
Dec 11, 2018 $74.15 $74.35 $73.95 $74.25 3 552 633
Dec 10, 2018 $73.92 $74.13 $73.82 $74.09 5 269 119
Dec 07, 2018 $73.66 $74.38 $73.64 $73.95 5 082 622
Dec 06, 2018 $73.62 $73.86 $73.47 $73.78 10 019 119
Dec 04, 2018 $73.52 $74.12 $73.45 $73.69 12 235 118
Dec 03, 2018 $73.68 $73.92 $73.40 $73.50 44 215 237
Nov 30, 2018 $45.81 $47.29 $44.51 $46.38 1 701 841
Click to get the best stock tips daily for free!

About TESARO

TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally. Its product portfolio consist of Rolapitant, a neurokinin-1 receptor antagonist, which is in phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly p... TSRO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT